Table I.
Characteristics of the Cancer and Control groups
| Characteristics applicable to both groups | Survivorship Group (N=171) | Control Group (N= 97) | P-value |
|---|---|---|---|
| Age in years, median (range) | 12.05 (4.23, 22.4) | 10.99 (1.14, 18.95) | 0.0222 |
| Gender, N (%) | 0.0021 | ||
| Male | 96 (56.1) | 35 (36.1) | |
| Female | 75 (43.9) | 62 (63.9) | |
| Race/Ethnicity, N (%) | <0.0011 | ||
| Caucasian non-Hispanic | 146 (85.4) | 67 (69.1) | |
| African American | 12 (7.0) | 24 (24.7) | |
| Hispanic | 6 (3.5) | 5 (9.7) | |
| Asian | 6 (3.5) | 1 (1.0) | |
| American Indian or Alaska Native | 1 (0.6) | 0 (0) | |
| BMI Z-score, median (range) | 0.96 (−2.91, 3.51) | 0.51 (−3.1, 2.98) | 0.0112 |
| BMI Z-score over 85th percentile, N (%) | 0.0661 | ||
| Overweight | 71 (41.8) | 29 (29.9) | |
| Not overweight | 99 (58.2) | 68 (70.1) | |
| Characteristic applicable to survivorship group only | |||
| Diagnosis, N (%) | |||
| Acute lymphoblastic leukemia | 121 (70.8) | ||
| Lymphoma | 36 (21.1) | ||
| Langerhans cell histiocytosis | 13 (7.6) | ||
| AML | 1 (0.6) | ||
| Time since completing therapy in years, median (range) | 2.68 (0.03, 10.83) | ||
| Past history vitamin D deficiency, N (%) | 3 (1.8) | ||
| Cumulative steroid dosing, (N=165), median (range) | 7057 (600, 17,524) | ||
| Past history of osteonecrosis N (%) | 14 (8.2) | ||
Body mass index is abbreviated as BMI. The p values shown are for the difference between groups and use either
1
Fisher’s exact test or
2
Wilcoxon rank sum test. Cumulative steroid dose is expressed as prednisone equivalents in mg/m2